Compare Fortinet Inc (FTNT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Moderna, Inc. — how do they compare? Fortinet Inc trades at $163.27 (market cap $118.78B), while Moderna, Inc. trades at $62.24 (market cap $24.18B). The key difference: Fortinet Inc is far larger — about 4.9× Moderna, Inc.'s market cap, and Fortinet Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| FTNT | MRNA | |
|---|---|---|
Market Cap | $118.78B | $24.18B |
Sector | Technology | Health |
52-Week High | $168.29 | $81.80 |
52-Week Low | $75.23 | $22.36 |
Enterprise Value | $115.21B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $164.21, up 2.86% in the last session, reflecting strong momentum as it approaches its consensus price target of $174.50. The stock exhibits bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $0.90 versus $0.746 expected. Revenue growth remains robust, climbing to $6.80 billion in 2025, with a net income margin of 28.17%. Recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
The outlook is positive, supported by solid fundamentals and analyst optimism, though elevated valuation ratios like a P/E of 57.2 pose risks. Competition and market volatility are concerns, but institutional buying and bullish ratings suggest further upside potential.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
